Rivopharm
About Rivopharm
Rivopharm is a Healthcare company, and was acquired by Laprophan in October 2025. Pharmaceutical production and distribution of generic drugs for psychiatric, antidiabetic, and other therapies. Rivopharm offers products and services including Repaglinide and Nicorandil. Its focus areas include Pharmaceuticals, Generic Drugs and Therapeutic Drugs. Its legal entity is Rivopharm SA.
Company details
Rivopharm is identified as a pharmaceutical entity where over 200 individuals are employed at its facility in Manno, Switzerland, to develop drugs for psychiatric, antidepressant, anti-inflammatory, epileptic, and diabetic treatments. The company, part of the Rivopharm group established in 1961, operates in more than 50 countries, with a focus on integrating innovation, technology, and prevention. Emphasis is placed on fostering dialogue with medical communities to ensure quality and respect for individuals in its processes.
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website rivopharm.ch
- Social LinkedIn
- Acquired by Laprophan (Oct 2025)
- Legal Name Rivopharm Sa
Products & Services of Rivopharm
Rivopharm offers a comprehensive portfolio of products and services, including Repaglinide and Nicorandil.
Repaglinide is developed as a generic antidiabetic medication for the management of diabetes.
Nicorandil is produced as a generic coronary vasodilator for cardiovascular applications.
Investors in Rivopharm
Rivopharm has secured backing from 1 investor. Prominent investors backing the company include Laprophan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Generic drugs are manufactured by Laprophan in Casablanca, Morocco. | 1949 | laprophan.com | Casablanca, Morocco |
Investor details for Rivopharm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Rivopharm
Rivopharm is identified as a pharmaceutical entity where over 200 individuals are employed at its facility in Manno, Switzerland, to develop drugs for psychiatric, antidepressant, anti-inflammatory, epileptic, and diabetic treatments. The company, part of the Rivopharm group established in 1961, operates in more than 50 countries, with a focus on integrating innovation, technology, and prevention. Emphasis is placed on fostering dialogue with medical communities to ensure quality and respect for individuals in its processes.
Rivopharm offers Repaglinide and Nicorandil.
Rivopharm has 1 investor. Key investors include Laprophan.
Rivopharm operates through Rivopharm Sa.
Yes. Rivopharm was acquired by Laprophan in October 2025.